| This week's sponsor is IBM Watson Health. | | | Visually Explore Real-world Evidence…
...by disease/product, without programming, statistical, or clinical knowledge. Watch our Video
IBM Access and Value Connect: built on MarketScan® claims and Explorys® EHR databases. |
Today's Rundown Biotech IPO bonanza, again, as 5 go for collective $600M-plus in offerings Newron delays pivotal schizophrenia trials amid safety fears AstraZeneca pivots to early-stage cancer in search of a niche Viela Bio, China's Hansoh pen development pact potentially worth $220M-plus Icon buys up majority of MeDiNova to boost research site footprint Fred Hutchinson team uses gold nanoparticles to improve CRISPR gene editing Featured Story | | | Tuesday, May 28, 2019 Just before Memorial Day weekend, five biotech companies dropped their initial public offering plans, adding up to $611 million in anticipated cash. |
|
|
Top Stories Tuesday, May 28, 2019 Newron Pharmaceuticals has delayed the start of phase 2/3 schizophrenia studies at the request of the FDA. The agency requested the delay after seeing data from studies of evenamide in mice and dogs. Tuesday, May 28, 2019 AstraZeneca is set to prioritize the treatment of early-stage cancers under the leadership of oncology research chief José Baselga, M.D., Ph.D. Talking to The Wall Street Journal, Baselga sketched out why he thinks splitting off from the congested pursuit of late-stage cancers will benefit AstraZeneca and patients. Tuesday, May 28, 2019 AstraZeneca spinout Viela Bio and China’s Hansoh Pharmaceutical Group have struck a deal to develop and market the former’s autoimmune drug inebilizumab in China. Hansoh will develop it for neuromyelitis optica spectrum disorder and may expand into other inflammatory and autoimmune diseases as well as blood cancers. Tuesday, May 28, 2019 Acquisitive Icon is at it again as it snaps up a majority stake in British site network company MeDiNova Research with an option to buy out the remaining shares penned into the deal. Monday, May 27, 2019 The CRISPR-Cas9 gene editing system has been hailed as a promising solution to a range of genetic diseases, but the technology has proven difficult to deliver into cells. Scientists at Fred Hutchinson Cancer Research Center developed gold nanoparticles that can deliver CRISPR to mouse models of HIV and inherited blood disorders. | This week's sponsor is Medical Sensors Expo & Conference. | | | |
Resources Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 